Primary tabs

Therapeutic Modulation of TREM2 Activity

Researchers: 
Funding year(s): 
2016
Funding to date: 
$150,000

There is strong evidence that inflammation occurs in different stages of Alzheimer’s disease (AD). Understanding this process can help us to design new therapeutic approaches. TREM2 is a protein directly related to the inflammation process that occurs in the brain of patients with AD. Mutations in this protein increase the risk to develop AD up to threefold. A fragment of this protein, namely soluble TREM2 (sTREM2), increases at very early stages of AD, and this increase occurs in parallel to an increase of biomarkers for neuronal cell death. We have evidence that increased sTREM2 reflects a protective response; however, this could not be maintained in later stages of AD.